Trillium Therapeutics Inc. (TRIL) is a publicly traded company in the Unknown sector. Across all available filings, 6 corporate insiders have executed 55 transactions totaling $2.5M, demonstrating a bearish sentiment with -$2.5M in net insider flow. The most recent transaction on Nov 17, 2021 involved a transaction of 75 shares valued at $0.
No significant insider buying has been recorded for TRIL in the recent period.
No significant insider selling has been recorded for TRIL in the recent period.
Based on recent SEC filings, insider sentiment for TRIL is bearish with an Insider Alignment Score of 0/100 and a net flow of -$2.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Trillium Therapeutics Inc. (TRIL) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 6 insiders are actively trading TRIL stock, having executed 55 transactions in the past 90 days. The most active insider is Jan Skvarka (Executive), who has made 9 transactions totaling $1.6M.
Get notified when executives and directors at TRIL file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 17, 2021 | Harrison Rosemary | Executive | Disposition | 75 | $N/A | $0 | |
| Nov 17, 2021 | Edward Walker Paul | Executive | Disposition | 5,736,363 | $N/A | $0 | |
| Jul 7, 2021 | Uger Robert | Executive | Option Exercise | 3,646 | $0.30 | $1.1K | |
| Jul 7, 2021 | Uger Robert | Executive | Sale | 3,646 | $9.00 | $32.8K | |
| Jun 7, 2021 | Uger Robert | Executive | Sale | 3,646 | $8.27 | $30.2K | |
| Jun 7, 2021 | Uger Robert | Executive | Option Exercise | 3,646 | $0.32 | $1.2K | |
| May 12, 2021 | Skvarka Jan | Executive | Option Exercise | 23,802 | $0.31 | $7.4K | |
| May 12, 2021 | Skvarka Jan | Executive | Sale | 23,802 | $9.24 | $219.9K | |
| May 11, 2021 | Skvarka Jan | Executive | Option Exercise | 87,500 | $0.45 | $39.4K | |
| May 11, 2021 | Skvarka Jan | Executive | Option Exercise | 19,198 | $0.31 | $6.0K | |
| May 11, 2021 | Skvarka Jan | Executive | Sale | 106,698 | $9.20 | $981.6K | Large |
| May 7, 2021 | Uger Robert | Executive | Option Exercise | 3,646 | $0.31 | $1.1K | |
| May 7, 2021 | Uger Robert | Executive | Sale | 3,646 | $9.30 | $33.9K | |
| Apr 8, 2021 | Petrova Penka | Executive | Sale | 5,312 | $11.09 | $58.9K | |
| Apr 8, 2021 | Petrova Penka | Executive | Option Exercise | 2,604 | $3.36 | $8.7K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 24 | $2.5M | 89.8% |
Exercise(M) | 29 | $282.6K | 10.2% |
Disposition(D) | 2 | $0 | 0.0% |
Insider selling pressure at Trillium Therapeutics Inc. has increased, with 6 insiders executing 55 transactions across all time. Total sales of $2.5M significantly outpace purchases of $0, resulting in a net outflow of $2.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.